Lazcluze (Lazertinib Mesilate Monohydrate)

Lazertinib mesilate irreversibly binds to mutant forms of the EGFR protein, including the T790M resistance variant. By covalently blocking the ATP‑binding site, it halts downstream signaling pathways that drive cancer cell growth, leading to reduced tumor proliferation and increased cancer cell death.

The specific dose of Lazcluze is determined by the prescribing physician based on the patient’s clinical condition, disease stage, and other individual factors. Healthcare providers set the appropriate dosage and schedule in accordance with approved labeling and clinical guidelines.

Safety data for Lazcluze in pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be ruled out, it should be used only if the potential benefit justifies the possible risk. Women of child‑bearing potential should use effective contraception during treatment.

To request Lazcluze, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lazcluze belongs to the third‑generation EGFR tyrosine kinase inhibitor class, similar to osimertinib. Both target sensitizing and T790M resistance mutations, but Lazcluze may offer a distinct safety profile and pharmacokinetic characteristics. Choice between agents depends on individual patient factors, prior therapy, and physician judgment.

Lazcluze should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Lazcluze is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional to maintain consistent absorption.

The most serious adverse events include interstitial lung disease or pneumonitis, severe hepatic injury reflected by marked ALT/AST elevations, and QT interval prolongation that can lead to cardiac arrhythmias. Patients should promptly report new respiratory symptoms, jaundice, or palpitations to their physician.

Lazcluze is contraindicated in individuals with known hypersensitivity to lazertinib mesilate or any of its excipients. It should also be avoided in patients with severe hepatic impairment unless a specialist determines a safe dosing strategy, and in those with a history of serious QT prolongation without appropriate monitoring.